Idogen AB (OSTO:IDOGEN) ROE % Adjusted to Book Value: -244.56% (As of Mar. 2023)


OSTO:IDOGEN Idogen AB OSTO:IDOGEN
21 GF Score
Price kr0.12
View Full Analysis

What is Idogen AB ROE % Adjusted to Book Value?

Idogen AB OSTO:IDOGEN 21 ROE % Adjusted to Book Value is -244.56% as of Mar. 2023. GuruFocus rates OSTO:IDOGEN with a GF Score™ of 21/100.

Idogen AB's ROE % for the quarter that ended in Mar. 2023 was -990.47%. Idogen AB's PB Ratio for the quarter that ended in Mar. 2023 was 4.05. Idogen AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 was -244.56%.

Idogen AB ROE % Adjusted to Book Value Related Terms

Idogen AB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Idogen AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idogen AB ROE % Adjusted to Book Value Chart

Idogen AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -46.40 -44.06 -66.42 -54.36 -130.83

Idogen AB Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -151.11 -180.84 -171.55 -95.31 -244.56

OSTO:IDOGEN vs REGN, VRTX, MRNA: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Idogen AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Idogen AB ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Idogen AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Idogen AB's ROE % Adjusted to Book Value falls into.


OSTO:IDOGEN
21GF Score
Idogen AB OSTO:IDOGEN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idogen AB ROE % Adjusted to Book Value Calculation

Idogen AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-654.15% / 5.00
=-130.83%

Idogen AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-990.47% / 4.05
=-244.56%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -244.56% mean?
Idogen AB (OSTO:IDOGEN) has a ROE % Adjusted to Book Value of -244.56% as of Mar. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Idogen AB and its competitors.
Is Idogen AB's ROE % Adjusted to Book Value too high?
Idogen AB's current ROE % Adjusted to Book Value is -244.56%. Overall, Idogen AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Idogen AB's ROE % Adjusted to Book Value compare to REGN and VRTX?
Idogen AB's ROE % Adjusted to Book Value of -244.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Idogen AB and its competitors. Idogen AB's current ROE % Adjusted to Book Value is -244.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idogen AB stock overvalued right now?
Idogen AB (OSTO:IDOGEN) has a current ROE % Adjusted to Book Value of -244.56%. The current ROE % Adjusted to Book Value is -244.56%. Idogen AB's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Idogen AB (OSTO:IDOGEN), the current ROE % Adjusted to Book Value is -244.56% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Idogen AB Business Description

Address Medicon Village, Scheelevagen 2, Lund, SWE, 223 81
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.
21GF Score

Get the complete analysis for OSTO:IDOGEN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price